Psychedelic and ketamine research trials in Brazil
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
18 registered studies are counted in Brazil. By compound: 2 psilocybin, 5 DMT, 6 ayahuasca, 7 ketamine and 1 ibogaine. By registry status: 8 recruiting, 1 not yet recruiting, 6 completed, 1 withdrawn and 2 status not reported. By phase: 1 early phase 1, 5 phase 1, 5 phase 2, 1 phase 3, 2 phase 4, 3 not applicable and 1 not reported. Reported start years run from 2014 (earliest) to 2026 (latest). Studies are linked to 9 institutions.
Country is taken from the research site linked to each registry record. A study counts once, and a study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
Recruiting now
9 of the 18 counted studies are listed in the registry as recruiting (8) or not yet recruiting (1), newest start first. Status is reported by study teams and can be out of date. PsychoactiveMap does not recruit, screen or refer anyone; eligibility and contact details are on each registry record.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| Inhaled DMT for Major Depressive Disorder | NCT07562191 | Recruiting | Phase 2 | 2026-08-01 | Universidade Federal do Rio Grande do Norte, Fortaleza |
| Effects of a Sigle Dose of Ayahuasca in Patients With Psychogenic Non-epileptic Seizures: an Open Label Clinical Trial | NCT07747324 | Recruiting | Phase 1 | 2026-07-01 | University of Sao Paulo, Ribeirão Preto |
| Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin. | NCT07732166 | Recruiting | Early Phase 1 | 2026-04-01 | Pontifícia Universidade Católica do Rio de Janeiro, Rio de Janeiro |
| Esketamine Versus Crisis Response Planning Versus Optimized Treatment as Usual for Suicide Prevention: A Pragmatic Controlled Trial in Two Brazilian Cities | NCT07120477 | Recruiting | Phase 4 | 2026-01-01 | University of Sao Paulo, Ribeirão Preto |
| Ayahuasca, Esketamine and PTSD | NCT07317206 | Recruiting | Phase 2 | 2025-12-20 | University of Sao Paulo, Ribeirão Preto |
| Ayahuasca, Esketamine and Body Image Perception | NCT07317219 | Recruiting | Not applicable | 2025-12-20 | University of Sao Paulo, Ribeirão Preto |
| Ayahuasca, Esketamine and Premenstrual Symptoms | NCT07317232 | Recruiting | Not applicable | 2025-12-20 | University of Sao Paulo, Ribeirão Preto |
| Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and/or Behavior in Adolescents | NCT06957704 | Not yet recruiting | Phase 3 | 2025-05-01 | Federal University of São Paulo, São Paulo |
| Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression: a Phase 2a Pilot Randomized Clinical Trial (COGUNILA) | NCT06898606 | Recruiting | Phase 1 | 2024-09-05 | Federal University of Latin American Integration, Foz do Iguaçu |
At a glance
- 18 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 2 |
| DMT | 5 |
| Ayahuasca | 6 |
| Ketamine | 7 |
| Ibogaine | 1 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 8 | 44% |
| Not yet recruiting | 1 | 6% |
| Completed | 6 | 33% |
| Withdrawn | 1 | 6% |
| Status not reported | 2 | 11% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 1 | 6% |
| Phase 1 | 5 | 28% |
| Phase 2 | 5 | 28% |
| Phase 3 | 1 | 6% |
| Phase 4 | 2 | 11% |
| Not applicable | 3 | 17% |
| Not reported | 1 | 6% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 9 |
| 2020 to 2023 | 6 |
| 2015 to 2019 | 1 |
| 2010 to 2014 | 2 |
All counted studies
All 18 counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| Inhaled DMT for Major Depressive Disorder | NCT07562191 | Recruiting | Phase 2 | 2026-08-01 | Universidade Federal do Rio Grande do Norte, Fortaleza |
| Effects of a Sigle Dose of Ayahuasca in Patients With Psychogenic Non-epileptic Seizures: an Open Label Clinical Trial | NCT07747324 | Recruiting | Phase 1 | 2026-07-01 | University of Sao Paulo, Ribeirão Preto |
| Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin. | NCT07732166 | Recruiting | Early Phase 1 | 2026-04-01 | Pontifícia Universidade Católica do Rio de Janeiro, Rio de Janeiro |
| Esketamine Versus Crisis Response Planning Versus Optimized Treatment as Usual for Suicide Prevention: A Pragmatic Controlled Trial in Two Brazilian Cities | NCT07120477 | Recruiting | Phase 4 | 2026-01-01 | University of Sao Paulo, Ribeirão Preto |
| Ayahuasca, Esketamine and PTSD | NCT07317206 | Recruiting | Phase 2 | 2025-12-20 | University of Sao Paulo, Ribeirão Preto |
| Ayahuasca, Esketamine and Body Image Perception | NCT07317219 | Recruiting | Not applicable | 2025-12-20 | University of Sao Paulo, Ribeirão Preto |
| Ayahuasca, Esketamine and Premenstrual Symptoms | NCT07317232 | Recruiting | Not applicable | 2025-12-20 | University of Sao Paulo, Ribeirão Preto |
| Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and/or Behavior in Adolescents | NCT06957704 | Not yet recruiting | Phase 3 | 2025-05-01 | Federal University of São Paulo, São Paulo |
| Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression: a Phase 2a Pilot Randomized Clinical Trial (COGUNILA) | NCT06898606 | Recruiting | Phase 1 | 2024-09-05 | Federal University of Latin American Integration, Foz do Iguaçu |
| Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression | NCT06094907 | Completed | Phase 2 | 2023-10-09 | Universidade Federal do Rio Grande do Norte, Natal |
| Safety and Tolerability of DMT in Healthy Adults | NCT05901012 | Completed | Phase 1 | 2023-04-26 | Universidade Federal do Rio Grande do Norte, Natal |
| Ibogaine in the Treatment of Alcoholism: an Open-label Escalating-dose Trial | NCT03380728 | Completed | Phase 2 | 2022-10-30 | University of Sao Paulo, Ribeirão Preto |
| Ayahuasca and Esketamine for Major Depression | NCT07212946 | Completed | Phase 2 | 2022-10-30 | University of Sao Paulo, Ribeirão Preto |
| Clinical Study of DMT in Healthy Adults | NCT05573568 | Completed | Phase 1 | 2022-06-01 | Biomind Labs Inc., Natal |
| Naturalistic Study of Ketamine in the Treatment of Depression | NCT05249309 | Status not reported | Not reported | 2021-05-01 | Hospital de Clinicas de Porto Alegre, Porto Alegre |
| Intramuscular Ketamine Versus Aripiprazole and Escitalopram in the Treatment of Resistant Depression | NCT04234776 | Status not reported | Phase 4 | 2018-04-03 | University of Sao Paulo, Blumenau |
| Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression | NCT02914769 | Completed | Phase 1 | 2014-02-01 | Universidade Federal do Rio Grande do Norte, Natal |
| Ketamine Use in Electroconvulsive Therapy | NCT02012335 | Withdrawn | Not applicable | 2014-01-01 | Hospital de Clinicas de Porto Alegre, Porto Alegre |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | DMT | Ayahuasca | Ketamine | Ibogaine
Institution hubs in this country
Institutions in this country with at least 3 counted studies. The number is that institution's own count of studies, which can include studies not shown above if the registry lists them under another country.
- University of Sao Paulo: 7 studies
- Universidade Federal do Rio Grande do Norte: 3 studies
Condition hubs
Condition hubs that include studies counted in this country, with the number of those studies. Conditions are matched by keyword on registered titles, so one study can appear under more than one condition.
| Condition hub | Studies in this country |
|---|---|
| Depression | 9 |
| Suicidal ideation and suicide risk | 3 |
| Treatment-resistant depression | 3 |
| Alcohol use disorder | 1 |
| Bipolar disorder | 1 |
| Post-traumatic stress disorder | 1 |
Other country hubs
United States | Canada | Switzerland | United Kingdom | France | Israel | China | Netherlands | Australia | Austria | Germany | Spain | Sweden | Argentina | Belgium | Egypt | Mexico | Poland | Taiwan | Ireland | Czech Republic | Denmark | Finland